745 related articles for article (PubMed ID: 16181413)
1. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
2. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
4. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
6. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
[TBL] [Abstract][Full Text] [Related]
9. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
Gal S; Fridkin M; Amit T; Zheng H; Youdim MB
J Neural Transm Suppl; 2006; (70):447-56. PubMed ID: 17017567
[TBL] [Abstract][Full Text] [Related]
10. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons.
Zheng H; Youdim MB; Weiner LM; Fridkin M
Biochem Pharmacol; 2005 Nov; 70(11):1642-52. PubMed ID: 16226724
[TBL] [Abstract][Full Text] [Related]
11. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
12. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.
Mechlovich D; Amit T; Mandel SA; Bar-Am O; Bloch K; Vardi P; Youdim MB
J Pharmacol Exp Ther; 2010 Jun; 333(3):874-82. PubMed ID: 20237072
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.
Pollak Y; Mechlovich D; Amit T; Bar-Am O; Manov I; Mandel SA; Weinreb O; Meyron-Holtz EG; Iancu TC; Youdim MB
J Neural Transm (Vienna); 2013 Jan; 120(1):37-48. PubMed ID: 22446839
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.
Kupershmidt L; Amit T; Bar-Am O; Youdim MB; Weinreb O
Mech Ageing Dev; 2012 May; 133(5):267-74. PubMed ID: 22426424
[TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Youdim MBH
J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696
[TBL] [Abstract][Full Text] [Related]
16. Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.
Zheng H; Youdim MB; Fridkin M
ACS Chem Neurosci; 2010 Nov; 1(11):737-46. PubMed ID: 22778810
[TBL] [Abstract][Full Text] [Related]
17. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Youdim MB
Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
19. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
Youdim MB; Kupershmidt L; Amit T; Weinreb O
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
[TBL] [Abstract][Full Text] [Related]
20. Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Jiang X; Guo J; Lv Y; Yao C; Zhang C; Mi Z; Shi Y; Gu J; Zhou T; Bai R; Xie Y
Bioorg Med Chem; 2020 Jun; 28(12):115550. PubMed ID: 32503694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
